Roche Teams Up with Zealand Pharma in $5.3 Billion Push Toward Obesity Breakthrough

May 19, 2025

Swiss healthcare leader Roche has entered a strategic alliance with Danish biotech innovator Zealand Pharma , committing up to $5.3 billion to co-develop and bring to market a new obesity therapy known as petrelintide.

Deal Structure and Funding: Zealand Pharma is set to receive an initial payment of $1.65 billion, with the potential to earn up to $5.3 billion depending on the achievement of specific development and commercial milestones.

Global Marketing Strategy:The two firms will jointly manage the drug's rollout across the United States and Europe, equally dividing both revenue and costs. Outside these territories, Roche will take the lead in sales while Zealand will benefit from royalty payments.

Why Petrelintide Stands Out:Petrelintide, a synthetic version of the hormone amylin, is designed for weekly injections. It shows promise for promoting significant weight loss with fewer adverse effects than current anti-obesity drugs.

Focus on Combination Innovation:The partnership also includes plans to create a combined treatment using petrelintide and Roche 's CT-388-a dual-action GLP-1/GIP receptor agonist-aiming to boost overall therapeutic impact.

Investor Reaction and Market Shifts:Following the announcement, Zealand Pharma 's stock jumped 25 percent;, while rival Novo Nordisk experienced a 5 percent; dip, underscoring the potential disruption this collaboration may bring to the weight-loss drug sector. This news previously appeared on Thestreet.

Over the current book year the total revenue from the company in Basel will be 63.53 billion CHF (consensus estimates). The expected revenue would be a record for the company. This is slightly more than 2025's revenue of 60.5 billion CHF.

Historical revenues and results Roche plus estimates 2025

Roche facility Woerden ©

Roche

The analysts anticipate for 2025 a record net profit a 15.73 billion CHF. Most of the analysts anticipate on a profit per share of 20.19 CHF. The PE-ratio therefore is 12.86.

Huge dividend Roche

Per share the analysts expect a dividend of 9.92 CHF per share. Roche 's dividend yield thus equals 3.82 percent. The average dividend yield of the pharmaceutical companies equals a good 2.07 percent.

Based on the current number of shares Roche 's market capitalization equals 179.34 billion CHF.

Historical stock prices Roche

On Friday the stock closed at 259.7 CHF.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

Other stock news

2008 best year, 2009 worst year for Roche

Roche inks potential $3B multi-target strategic collaboration with Shape Therapeutics

Analysts expect over 2020 rising revenue Roche

Analysts expect revenue increase Roche

Stock Roche goes ahead in Switzerland in terms of dividend yields

Analysts say Roche is low priced

Analysts expect over 2018 rising revenue Roche, relatively high dividend

Sector news

Analysts estimate for 2024 rising sales UCB

Analysts anticipate for 2024 on revenue increase Astrazeneca, high dividend yield

High dividend yield Sanofi-Aventis

Sanofi-Aventis in top French dividend returns

Novartis among highest Swiss dividend stocks

Analysts expect over 2023 revenue increase UCB

Pfizer CEO Bourla says company prepared if modified COVID vaccine required

National news

Analysts expect over 2024 revenue expansion UBS

Currently quite high dividend BB Biotech

Analysts: more sales ABB

Analysts: less sales Sonova

Analysts expect over 2024 revenue increase Adecco, quite high dividend

Clariant among highest Swiss dividend stocks

Press news

Inventus Completes Early Warrant Exercise Incentive Program

Partners Value Investments Inc. Announces Q1 2025 Interim Results

ValOre and South Atlantic Provide Update on Proposed Amalgamation

ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages NET Power Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NPWR, NPWR.WS

Ryman Hospitality Properties, Inc. Announces Upsizing and Pricing of $625 Million of Senior Notes Due 2033

Barrack, Rodos & Bacine Notifies Shareholders of Open Lending Corp. (LPRO) of a Securities Class Action Lawsuit

Partners Value Investments L.P. Announces Q1 2025 Interim Results

About us	Network	Partners
Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos	Analist.nlLinksISIN Glossary	MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x